BLOCK et al., 2000 - Google Patents
Secretion of human hepatitis B virus is inhibited by the imino sugar N-butyldeoxynojirimycin (antivirals/glycosylation)BLOCK et al., 2000
- Document ID
- 14050122048001386907
- Author
- BLOCK T
- LU X
- PLATT F
- FOSTER G
- GERLICH W
- BLUMBERG B
- DWEK R
- Publication year
- Publication venue
- Hepatitis B And The Prevention Of Primary Cancer Of The Liver: Selected Publications of Baruch S Blumberg
External Links
Snippet
The imino sugar N-butyldeoxynojirimycin (NBDNJ) is a potent Inhibitor of tbe oligosaccharide-trimming enzyme α-glucosidase I. Hepatitis B virus (HBV) contains three surface proteins (HBs proteins) of different sizes that are singly or doubly N-glycosylated and …
- 230000028327 secretion 0 title abstract description 14
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse Transcribing DNA Viruses
- C12N2730/00011—Reverse Transcribing DNA Viruses
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse Transcribing RNA Viruses
- C12N2740/00011—Reverse Transcribing RNA Viruses
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Block et al. | Secretion of human hepatitis B virus is inhibited by the imino sugar N-butyldeoxynojirimycin. | |
| EP0414374B1 (en) | Novel antigens and methods for their preparation | |
| LU et al. | Evidence that N-linked glycosylation is necessary for hepatitis B virus secretion | |
| Klingmüller et al. | Hepadnavirus infection requires interaction between the viral pre-S domain and a specific hepatocellular receptor | |
| Hasegawa et al. | Enhanced replication of a hepatitis B virus mutant associated with an epidemic of fulminant hepatitis | |
| Jin et al. | Human T cell response to the surface antigen of hepatitis B virus (HBsAg). Endosomal and nonendosomal processing pathways are accessible to both endogenous and exogenous antigen. | |
| Ryu et al. | Assembly of hepatitis delta virus particles | |
| Binder et al. | Antiviral protection by CD8+ versus CD4+ T cells. CD8+ T cells correlating with cytotoxic activity in vitro are more efficient in antivaccinia virus protection than CD4-dependent IL | |
| EP0522030B1 (en) | Hepatitis b vaccine | |
| Alberti et al. | Antibody response to pre-S2 and hepatitis B virus induced liver damage | |
| EP0739205B1 (en) | Use of n-alkyl derivatives of 1,5-dideoxy-1,5-imino-d-glucitol for the treatment of hepatitis b virus infections | |
| Weiss et al. | Anti-hepatitis B virus activity of N-acetyl-L-cysteine (NAC): new aspects of a well-established drug | |
| Scaglioni et al. | Characterization of hepatitis B virus core mutants that inhibit viral replication | |
| US7452696B2 (en) | Recombinant plasmid and method for expressing hepatitis B viral antigens and virions in vivo | |
| US20050053625A1 (en) | Method of treating viral infections | |
| US6103519A (en) | Antigens and methods therefor | |
| BLOCK et al. | Secretion of human hepatitis B virus is inhibited by the imino sugar N-butyldeoxynojirimycin (antivirals/glycosylation) | |
| Taylor | Human hepatitis delta virus | |
| Schlipköter et al. | Different outcomes of chronic hepatitis delta virus infection in woodchucks | |
| CN116510016B (en) | Application of matrix metalloproteinase-9 inhibitor in the preparation of drugs for treating chronic HBV infection | |
| Bonino et al. | The impact of molecular biology in the diagnosis and management of viral hepatitis | |
| Al-Jabri et al. | Essential immune responses to hepatitis B virus infection | |
| Heijtink et al. | Anti-pre-S (2) analysis after hepatitis B vaccination in haemodialysis patients | |
| US5989865A (en) | Hepatitis B vaccine | |
| AU642729C (en) | Hepatitis B vaccine |